Prevalence de l'anticorps dirige contre les souches courantes du virus de !'influenza dans une enquete canadienne menee en 1992 et estimations quant aux infections
1976. It is one of the surveillance systems used to monitor influenza activity and gauge susceptibility to currently circulating and emerging influenza virus strains. Similar serosurveys are conducted in France and Norway as part of their influenza surveillance systems. In Canada, the influenza serosurvey is part of an annual collaborative influenza surveillance program between provincial laboratories and the Laboratory Centre for Disease Control (LCDC).
MATERIALS AND METHODS
The sampling method does not ensure representation of the entire population but incurs relatively little cost, as sera are aliquots of specimens already submitted to the laboratories for routine monitoring of patient health, screening tests or other diagnostic reasons. Six hundred and thirty sera with age and geographic area identifiers were submitted to the Bureau of Microbiology, LCDC by the provincial public health laboratories.
Laboratories selected 10 sera from each of four age groups (0 to 14 years, 15 to 34 years, 35 to 64 years, and 65 years and older) from among specimens received during a one-week sampling period starting May 31, 1992. The provincial laboratories of public health for Northem Alberta and Southem Alberta each submitted 40 sera. For Ontario and Quebec, a four-week collection period was used so that their relatively larger populations would have a correspondingly larger representation in the total data. The sera collection dates were chosen to fall between influenza seasons and to precede the 1992 vaccine release date. These sera were tested for hemagglutination inhibiting (HI) antibodies against the 1992-93 influenza vaccine strains: A/Bei- For 1991 and 1992 influenza survey sera, the percentage of samples having titres of 1:40 or greater by the HI antibody test were calculated. HI antibody titres of 1:40 or greater following vaccination have been associated with reduced influenza illness and infection and are widely presumed to indicate some degree of protection against similar strains (1) .
RESULTS

Influenza (HaN2) immunity:
From the data in Table 1 and Figure 1A (all regions), it can be seen that for age group 0 to 14 years there was nearly a threefold increase (from 25% in 1991 to 74% in 1992) in the percentage of sera with protective antibody titre of 1:40 or greater to A/Beijing/353/89 (HsN2). The two age groups 15 to 34 and 35 to 64 years showed increases in percentages of sera with protective antibody of greater than twofold and just under twofold for the group aged greater than 65 years ( Table 1 ).
The data of Table 2 show the percentage of sera by age group and geographic region having HI antibody to A/Beijing/353/89 (HsN2)-like strains. Comparison of the data for 1992 and 1991 (2) is presented in Figure 1 . In each region, the most dramatic differences are among those aged 0 to 14 years. However, in every age group, and in every region except for age groups 15 to 34 and 35 to 64 years in the Atlantic region, there were large increases in the percentages of individuals with HI antibody titres of 1:40 or greater to A/Beijing/353/89 (HsN2)-like viruses in 1992 ( Figure 1B,C,D,E) . This It is recognized that the sampling protocol does not provide a truly random sample, that there are weighting biases in the sampling and thus considerable uncertainty in extending the sample findings to the population as a whole. Nevertheless, if the estimated population number (5) in each age group of Table 1 is multiplied by the difference in proportion of sample from that age group that has protective antibody in 1992 relative to 1991, the result is an estimate of 9.4 million more people in 1992 having HI antibody titres of 1:40 or greater to A/Beijing/353 / 89 than in 1991.
One estimate is that 3.6 million doses of influenza vaccine were distributed in Canada in 1991. If one assumes that 20% of people vaccinated were already immune to A/Beijing/353/89 (Table 1) (Table 1 ). In the serosurvey data (not shown) it was noted that individuals who had elevated titres to one of the two H 1 N 1 test antigens almost always had a similar titre to the other H1N1 antigen. This indicates a great deal of cross-reactivity of human serum antibody with both H 1 N 1 antigens used in the survey. Table 2 indicates that the percentage of sera showing immunity to influenza A (HIN!l varied greatly between age groups within and between the various regions of Canada. Most influenza A (HJNI) isolates came from western Canada in the 1991-92 season and the highest percentage of immune individuals (53%) (all ages combined) was seen in western Canada, while the lowest percentage immunity levels (all ages combined) occurred in Quebec and Ontario. Influenza B immunity: From Table 1 , it is seen that there were slightly higher percentages of sera with protective antibody titres to B/Panama/45/90 in 1992 compared with 1991. There was relatively little influenza B activity reported in Canada in the 1991-92 season; however, even when the virus was detected during peak season, it was not successfully cultivated for characterization. Therefore, it is possible that there was limited circulation of influenza B that was not readily detected apart from the reported laboratory diagnoses in Newfoundland, Ontario and Manitoba (3). Alternatively, the 8% increase in 1992 in sera having an antibody titre of at least 1:40 may have resulted partially from vaccination.
DISCUSSION
It is unlikely thatA/Beijing/353/89 (H3N2) will have the same impact in the 1992-93 season as in the previous season because of the relatively high levels of immunity that presently exist, especially in the youngest age group. More than half of the laboratory confirmed cases of influenza with age of patient given occurred in those under 15 years of age (3) . However, tests on serosurvey specimens from the 15 to 34 and 35 to 64 year age groups in various regions of the country indicated that there were also significant numbers of susceptible individuals among those sampled (Table 2, Figure 1) .
A/Texas/36/91 (H1N1) emerged to cause significant infection along with the closely related A/Taiwan/ 1 I 86 in the Atlantic and south Atlantic regions of the United States in the 1991-92 season. We found that there was considerable cross-reactivity in human serum antibodies to both H1N1 strains used in the survey, and that a moderately high percentage (49 to 57%) of the two younger age group specimens had antibody to these strains. Therefore, the impact of H1N1 strains resembling those in the survey was expected to be light to moderate in the 1992-93 season. For influenza B, it was seen that considerable potential for activity existed given the relatively low percentage of samples (27% over all ages) that displayed protective antibody.
As of February 5, 1993 laboratory isolation/detection surveillance (Peter Zabchuc, Bureau of Communicable Disease Epidemiology, LCDC) indicated that there were 94 influenza B reports and 14 reports of influenza A indicative of a relatively light influenza activity, but with influenza B predominating. Similarly, the 1991 serosurvey data (2) ( Table 1) Sample size, selection, origin of specimens within a province and test variation limit the degree to which the percentage immunity figures can be taken to represent the precise level of immunity in any one province and individual age group. However, past experience has shown that the serological data tend to reflect the past year's influenza activity or lack of it for the country as a whole. to contribute to improved prediction of the potential for activity in the coming year, to provide early quantification of the need for vaccination, and to provide specific information for risk communications to the media which helps to control the circulation of false or exaggerated rumours.
